Kenneth Hoberman
Chief Operating Officer en STEMLINE THERAPEUTICS, INC. .
Fortuna: 4 M $ al 31/03/2024
Perfil
Kenneth Hoberman is currently the Vice Chairman at Lirum Therapeutics, Inc., an Independent Director at TG Therapeutics, Inc., an Independent Director at Nuvectis Pharma, Inc., and the Secretary & Chief Operating Officer at Stemline Therapeutics, Inc. Previously, he served as the Vice President-Corporate & Business Development at Keryx Biopharmaceuticals, Inc. from 2004 to 2012.
Mr. Hoberman completed his undergraduate degree at Boston University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
TG THERAPEUTICS, INC.
0.16% | 28/09/2023 | 242 685 ( 0.16% ) | 4 M $ | 31/03/2024 |
NUVECTIS PHARMA, INC.
0.41% | 16/06/2023 | 73 140 ( 0.41% ) | 599 748 $ | 31/03/2024 |
Cargos activos de Kenneth Hoberman
| Empresas | Cargo | Inicio |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Chief Operating Officer | 01/01/2013 |
| TG THERAPEUTICS, INC. | Director/Board Member | 15/12/2014 |
| NUVECTIS PHARMA, INC. | Director/Board Member | 01/07/2021 |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Director/Board Member | 01/11/2021 |
Antiguos cargos conocidos de Kenneth Hoberman.
| Empresas | Cargo | Fin |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Corporate Officer/Principal | 01/01/2012 |
Formación de Kenneth Hoberman.
| Boston University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
 | Health Technology |
| Empresas privadas | 3 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
| Nuvectis Pharma, Inc. |
- Bolsa de valores
- Insiders
- Kenneth Hoberman
